Abstract
Cancer, also known as a malignant tumor, has become one of the top burdens of disease for few decades, and it’s also the second lethal cause globally. With extensive efforts of oncology researches and clinical trials in the modern era, scientists have developed numbers of therapeutic approaches in the treatment of cancer. In this chapter, we introduce the existing conventional cancer therapeutic methods in two categories, the traditional cancer treatments and the novel tumor therapeutic modes. The former includes surgery, radiotherapy, hormone therapy, chemotherapy, and stem cell transplant, and the latter involves immunotherapy, targeted therapy, and gene therapy. We first give a brief introduction to each therapy from their history to the definition and list several examples for illustration. Then we discuss the combination of each treatment with other cancer therapies and risks of certain remedies. Particularly, we briefly demonstrate the nanomaterials in the application of targeted therapy. Besides, we also state some current obstructions of targeted therapy that needed to be overcome. Finally, there is the introduction of complementary and alternative medicine for the use of antineoplastic therapy, which we provide some information including the overview of some traditional medicine or whole medical systems.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Sudhakar A (2009) History of Cancer, ancient and modern treatment methods. J Cancer Sci Ther 1(2):1–4
Mukherjee S (2010) The emperor of all maladies: a biography of cancer. Scribner, New York
Urruticoechea A, Alemany R, Balart J et al (2010) Recent advances in cancer therapy: an overview. Curr Pharm Des 16(1):3–10. https://doi.org/10.2174/138161210789941847
Anand P, Kunnumakara AB, Sundaram C et al (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25(9):2097–2116
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551
Stacy Simon (2019) American Cancer Society. Facts & figures 2019: US cancer death rate has dropped 27% in 25 years. https://www.cancer.org/latest-news/facts-and-figures-2019.html. Accessed 15 Apr 2019
Diffen. Cancer vs. Tumor. https://www.diffen.com/difference/Cancer_vs_Tumor. Accessed 15 Apr 2019
World Health Organization (2018) Cancer. https://www.who.int/cancer/en/. Accessed 15 Apr 2019
Nall R (2018) Medical news today. What to know about cancer. https://www.medicalnewstoday.com/articles/323648.php. Accessed 15 Apr 2019
National Cancer Institute (2015) What is cancer. https://www.cancer.gov/about-cancer/understanding/what-is-cancer. Accessed 15 Apr 2019
David AR, Zimmerman MR (2010) Cancer: an old disease, a new disease or something in between? Nat Rev Cancer 10(10):728–733. https://doi.org/10.1038/nrc2914
Wust P, Hildebrandt B, Sreenivasa G et al (2002) Hyperthermia in combined treatment of cancer. Lancet Oncol 3(8):487–497
Hawkes N (2015) History of cancer treatment. https://www.raconteur.net/healthcare/history-of-cancer-treatment. Accessed 15 Apr 2019
National Cancer Institute. Types of Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types. Accessed 15 Apr 2019
Garrison FH (1966) Contributions to the history of medicine. W.B. Saunders Company, Philadelphia
Retief FP, Cilliers L (2001) Tumours and cancers in Graeco-Roman times. S Afr Med J 91(4):344–348
Introduction, Celsus, On Medicine. http://penelope.uchicago.edu/Thayer/E/Roman/Texts/Celsus/Introduction∗.html. Accessed 15 Apr 2019
Retief FP, Cilliers L (2011) Breast cancer in antiquity. S Afr Med J 101(8):513–515
Evans CH (2007) John hunter and the origins of modern orthopaedic research. J Orthop Res 25(4):556–560
Robinson DH, Toledo AH (2012) Historical development of modern anesthesia. J Investig Surg 25(3):141–149
Fox NJ (1988) Scientific theory choice and social structure: the case of Joseph Lister’s antisepsis, humoral theory and asepsis. Hist Sci 26(4):367–397
Wyld L, Audisio RA, Poston GJ (2015) The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 12(2):115–124. https://doi.org/10.1038/nrclinonc.2014.191
National Cancer Institute (2015) Surgery to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/surgery#TS. Accessed 15 Apr 2019
Canadian Cancer Society. Types of surgery. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/surgery/types-of-surgery/?region=on. Accessed 15 Apr 2019
Whitlock J (2018) Verywell health. What is open surgery? Is it right for you? https://www.verywellhealth.com/open-surgery-3157124. Accessed 15 Apr 2019
Medstarhealth. Endoscopic Surgery. https://www.medstarhealth.org/mhs/our-services/colon-and-rectal-surgery/treatments/endoscopic-surgery/. Accessed 15 Apr 2019
Mehra H (2017) Quora. Which is better, open surgery or laparoscopic surgery? https://www.quora.com/Which-is-better-open-surgery-or-laparoscopic-surgery. Accessed 15 Apr 2019
National Health Service. Overview – Laparoscopy (keyhole surgery). https://www.nhs.uk/conditions/laparoscopy/. Accessed 15 Apr 2019
Unger JG (2017) Medscape. Cryotherapy. https://emedicine.medscape.com/article/1125851-overview#a1. Accessed 15 Apr 2019
Rubinsky B (2000) Cryosurgery. Annu Rev Biomed Eng 2(1):157–187
National Cancer Institute (2003) National Cancer Institute Cryosurgery in Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types/surgery/cryosurgery-fact-sheet. Accessed 15 Apr 2019
Chi E (2016) Health line. Laser therapy. https://www.healthline.com/health/laser-therapy. Accessed 15 Apr 2019
Standford Health care. What Is Laser Surgery? https://stanfordhealthcare.org/medical-treatments/l/laser/types/laser-surgery.html. Accessed 15 Apr 2019
National Cancer Institute (2011) National Cancer Institute Lasers in Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types/surgery/lasers-fact-sheet. Accessed 15 Apr 2019
Hulse RM, Kenneth HL (1980) Hyperthermia in cancer therapy. West J Med 132(3):179–185
Van der Zee J (2002) Heating the patient: a promising approach? Ann Oncol 13(8):1173–1184
Desaulniers V (2019) The truth about cancer. Hyperthermia therapy: using heat to help heal cancer. https://thetruthaboutcancer.com/hyperthermia-treatment/. Accessed 15 Apr 2019
National Cancer Institute (2011) National Cancer Institute Photodynamic Therapy for Cancer. https://www.cancer.gov/about-cancer/treatment/types/surgery/photodynamic-fact-sheet. Accessed 15 Apr 2019
National Health Service. Photodynamic therapy (PDT). https://www.nhs.uk/conditions/photodynamic-therapy/. Accessed 15 Apr 2019
Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380–387
Capella MAM, Capella LS (2003) A light in multidrug resistance: photodynamic treatment of multidrug-resistant tumors. J Biomed Sci 10(4):361–366
Wilson BC (2002) Photodynamic therapy for cancer: principles. Can J Gastroenterol Hepatol 16(6):393–396
Mayo Foundation for Medical Education and Research (2019) Robotic surgery. https://www.mayoclinic.org/tests-procedures/robotic-surgery/about/pac-20394974. Accessed 15 Apr 2019
NYU Langone Health. What is Robotic Surgery? https://med.nyu.edu/robotic-surgery/physicians/what-robotic-surgery. Accessed 5 May 2019
Lanfranco AR, Castellanos AE, Desai JP, Meyers WC (2004) Robotic surgery a current perspective. Ann Surg 239(1):14–21
US. Food and Drug Administration (2019) Caution when using robotically-assisted surgical devices in women’s health including mastectomy and other cancer-related surgeries: FDA Safety. Communication. https://www.fda.gov/medical-devices/safety-communications/caution-when-using-robotically-assisted-surgical-devices-womens-health-including-mastectomy-and. Accessed 5 May 2019
Wallace D, Cure medical. What is electrosurgery and how does it help cure cancer. http://www.curemedicalglobal.com/electrosurgery-help-cure-cancer/. Accessed 5 May 2019
Massarweh NN, Cosgriff N, Slakey DP (2006) Electrosurgery: history, principles, and current and future uses. J Am Coll Surg 202(3):520–530
Ratini M (2019) WebMD. What is a HIFU procedure? https://www.webmd.com/prostate-cancer/prostate-cancer-hifu-surgery#1. Accessed 5 May 2019
National Health Service. Prostate Cancer. https://www.nhs.uk/conditions/prostate-cancer/. Accessed 5 May 2019
DocDoc. What is High Intensity Focused Ultrasound (HIFU): overview, benefits, and expected results. https://www.docdoc.com.sg/info/procedure/high-intensity-focused-ultrasound/. Accessed 5 May 2019
American Academy of Dermatology (2007) What is Mohs surgery? https://www.aad.org/public/diseases/skin-cancer/what-is-mohs-surgery. Accessed 5 May 2019
Mayo Foundation for Medical Education and Research (2017) Mohs surgery. https://www.mayoclinic.org/tests-procedures/mohs-surgery/about/pac-20385222. Accessed 5 May 2019
Swanson NA (1983) Mohs surgery: technique, indications, applications, and the future. Arch Dermatol 119(9):761–773
Encyclopaedia Britannica (2017) Stereotaxic surgery. https://www.britannica.com/science/stereotaxic-surgery. Accessed 5 May 2019
Mayo Foundation for Medical Education and Research (2019) Stereotactic radiosurgery. https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526. Accessed 5 May 2019
Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M et al (2005) Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43(3):458–464
Cicalese L (2018) Medscape. What is the role of Percutaneous Ethanol Injection (PEI) in the treatment of Hepatocellular Carcinoma (HCC)? https://www.medscape.com/answers/197319-39253/what-is-the-role-of-percutaneous-ethanol-injection-pei-in-the-treatment-of-hepatocellular-carcinoma-hcc. Accessed 5 May 2019
Ansari D, Andersson R (2012) Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol 18(10):1003. https://doi.org/10.3748/wjg.v18.i10.1003
Shiina S et al (2012) Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 32(9):1434–1442
Canadian Cancer Society. Surgery in cancer treatment. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/surgery/?region=qc. Accessed 5 May 2019
American Cancer Society (2016) Chemotherapy side effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html. Accessed 5 May 2019
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7–17
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257
Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073–2087
Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039–1049
Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C et al (2015) Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev 2(3):CD011430. https://doi.org/10.1002/14651858.CD011430
Kumar L, Harish P, Malik PS, Khurana S (2018) Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer 42(2):120–128
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15
Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 13(1):195
American Cancer Society (2018) Risks of cancer surgery. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/surgery/risks-of-cancer-surgery.html. Accessed 5 May 2019
Whitlock J (2018) Verywell health. Understanding the risks involved when having surgery. https://www.verywellhealth.com/understanding-the-risks-involved-when-having-surgery-3156959. Accessed 5 May 2019
Chand M, Armstrong T, Britton G et al (2007) How and why do we measure surgical risk? J R Soc Med 100(11):508–512
Radiation Oncology Targeting Cancer. Radiation therapy. https://www.targetingcancer.com.au/radiation-therapy/brachytherapy/. Accessed 5 May 2019
National Cancer Institute (2019) Radiation therapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy. Accessed 5 May 2019
Foray N (2016) Victor Despeignes, the forgotten pioneer of radiation oncology. Int J Radiat Oncol Biol Phys 96(4):717–721
Thariat J et al (2013) Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol 10(1):52
Leszczynski K, Boyko S (1997) On the controversies surrounding the origins of radiation therapy. Radiother Oncol 42(3):213–217
Del Regato JA (1991) Milestones in therapeutic radiology. In: The role of high energy electrons in the treatment of cancer. Karger Publishers, Basel, pp 4–9
Mould RF (1998) The discovery of radium in 1898 by Maria Sklodowska-Curie (1867-1934) and Pierre Curie (1859-1906) with commentary on their life and times. Br J Radiol. 71(852):1229–1254
Metzenbaum M (1905) Radium: its value in the treatment of lupus, rodent ulcer, and epithelioma, with reports of cases. Int Clinics 14(4):21–31
Frame PW (1985) Radioactive curative devices and spas. Oak Ridger Newspaper
Holsti LR (1995) Development of clinical radiotherapy since 1896. Acta Oncol 34(8):995–1003. https://doi.org/10.3109/02841869509127225
Mitchell G (2013) The rationale for fractionation in radiotherapy. Clin J Oncol Nurs 17(4). https://doi.org/10.1188/13.CJON.412-417
Thwaites DI, Tuohy JB (2006) Back to the future: the history and development of the clinical linear accelerator. Phys Med Biol 51(13):R343
Bhattacharyya KB (2016) Godfrey Newbold Hounsfield (1919–2004): the man who revolutionized neuroimaging. Ann Indian Acad Neurol 19(4):448
Canadian Cancer Society. Radiation therapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/radiation-therapy/?region=qc. Accessed 5 May 2019
Hill R, Healy B, Holloway L, Kuncic Z, Thwaites D, Baldock C (2014) Advances in kilovoltage x-ray beam dosimetry. Phys Med Biol 59(6):R183
Baskar R, Lee KA, Yeo R, Yeoh K-W (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9(3):193
Canadian Cancer Society. External beam radiation therapy for cancer. https://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/radiation-therapy/external-radiation-therapy/?region=on. Accessed 5 May 2019
Radiation Oncology Targeting Cancer. Intensity-Modulated Radiation Therapy (IMRT). https://www.targetingcancer.com.au/radiation-therapy/ebrt/intensity-modulated-radiation-therapy-imrt/. Accessed 5 May 2019
National Cancer Institute (2018) External beam radiation therapy. https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/external-beam. Accessed 5 May 2019
Elekta (2019) Gamma knife treatment process. https://www.elekta.com/patients/gammaknife-treatment-process/. Accessed 5 May 2019
Radiation Oncology Targeting Cancer. Stereotactic Body Radiation Therapy (SBRT). https://www.targetingcancer.com.au/radiation-therapy/ebrt/stereotactic-body-radiation-therapy-sbrt/. Accessed 5 May 2019
Radiation Oncology Targeting Cancer. Image-Guided Radiation Therapy (IGRT). https://www.targetingcancer.com.au/radiation-therapy/ebrt/image-guided-radiation-therapy-igrt/. Accessed 5 May 2019
Kjellberg RN, Abe M (1988) Stereotactic Bragg peak proton beam therapy. In: Lunsford LD (ed) Modern stereotactic neurosurgery. Topics in neurological surgery. Springer, Boston, pp 463–470. https://doi.org/10.1007/978-1-4613-1081-5_36
Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A (2011) Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 84(1007):967–970
Bertelsen A, Hansen CR, Johansen J, Brink C (2010) Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol 95(2):142–148
Van Gestel D, van Vliet-Vroegindeweij C, Van den Heuvel F, Crijns W, Coelmont A, De Ost B et al (2013) RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol 8(1):37
Unak P (2002) Targeted tumor radiotherapy. Braz Arch Biol Technol 45:97–110
Persson L (1994) The auger electron effect in radiation dosimetry. Health Phys 67(5):471–476
Kassis AI (2003) Cancer therapy with Auger electrons: are we almost there? J Nucl Med 44(9):1479–1481
Sastry KSR (1992) Biological effects of the auger emitter iodine-125: a review. Report no. 1 of AAPM nuclear medicine task group no. 6. Med Phys 19(6):1361–1370
American Cancer Society. Internal radiation therapy (Brachytherapy). https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/internal-radiation-therapy-brachytherapy.html. Accessed 5 May 2019
Limbergen EV, Skowronek J, Pötter R (2012) The GEC ESTRO handbook of brachytherapy. https://www.wco.pl/zb/files/publication/fd9f39.pdf. Accessed 5 May 2019
Mayo Foundation for Medical Education and Research (2018) Brachytherapy. https://www.mayoclinic.org/tests-procedures/brachytherapy/about/pac-20385159. Accessed 5 May 2019
National Cancer Institute (2019) Brachytherapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/brachytherapy. Accessed 5 May 2019
Thomadsen BR, Williamson JF, Rivard MJ et al (2008) Anniversary paper: past and current issues, and trends in brachytherapy physics. Med Phys 35(10):4708–4723
Sun Myint A et al (2017) Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation? Br J Radiol 90(1080):20170175
Myint AS (2014) Novel radiation techniques for rectal cancer. J Gastrointest Oncol 5(3):212–217. https://doi.org/10.3978/j.issn.2078-6891.2014.031
Myint AS, Smith FML, Gollins S et al (2018) Dose escalation using contact X-ray brachytherapy after external beam radiotherapy as nonsurgical treatment option for rectal cancer: outcomes from a single-center experience. Int J Radiat Oncol Biol Phys 100(3):565–573. https://doi.org/10.1016/j.ijrobp.2017.10.022
Dutta SW, Showalter SL, Showalter TN, Libby B, Trifiletti DM (2017) Intraoperative radiation therapy for breast cancer patients: current perspectives. Breast Cancer Targets Ther 9:257
Belletti B, Vaidya JS, D’Andrea S, Entschladen F, Roncadin M, Lovat F et al (2018) Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res 14(5):1325–1332
Bergom C et al (2018) Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. Front Oncol 8:87
Rosenzweig KE et al (2000) The deep inspiration breath-hold technique in the treatment of inoperable non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 48(1):81–87
GenesisCare. Deep inspiration breath hold. https://www.genesiscare.com/uk/treatment/cancer/radiotherapy/deep-inspiration-breath-hold/. Accessed 5 May 2019
Latty D et al (2015) Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci 62(1):74–81
Stokkel MPM, Junak DH, Lassmann M, Dietlein M, Luster M (2010) EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 37(11):2218–2228
Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ et al (2012) The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 53(10):1633–1651
American Cancer Society (2017) Radiation for breast cancer. https://www.cancer.org/cancer/breast-cancer/treatment/radiation-for-breast-cancer.html. Accessed 5 May 2019
American Cancer Society (2018) Treatment of rectal cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/treating/by-stage-rectum.html. Accessed 5 May 2019
National Cancer Institute (2019) Cervical Cancer Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/cervical/patient/cervical-treatment-pdq#_180. Accessed 5 May 2019
American Cancer Society (2019) Treatment of bladder cancer, by stage. https://www.cancer.org/cancer/bladder-cancer/treating/by-stage.html. Accessed 5 May 2019
Canadian Cancer Society. Side effects of radiation therapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/radiation-therapy/side-effects-of-radiation-therapy/?region=qc. Accessed 5 May 2019
Johns Hopkins Medicine. Hormonal therapy. https://www.hopkinsmedicine.org/breast_center/treatments_services/medical_oncology/adjuvant_hormonal_therapy.html. Accessed 5 May 2019
National Cancer Institute (2015) Hormone therapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/hormone-therapy#THT. Accessed 5 May 2019
Beatson GT (1983) Classics in oncology: on the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. CA Cancer J Clin 33(2):108–121
American Cancer Society (2014) Evolution of cancer treatments: hormone therapy. https://www.cancer.org/cancer/cancer-basics/history-of-cancer/cancer-treatment-hormone-therapy.html. Accessed 5 May 2019
Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb 15:153
Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232–240
Magon N (2011) Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab 15(4):261
Moreau J-P, Delavault P, Blumberg J (2006) Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 28(10):1485–1508
Novara G, Galfano A, Secco S, Ficarra V, Artibani W (2009) Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol Int 82(3):249–255
Vachani C (2018) Oncolink. Hormone therapy: the basics. https://www.oncolink.org/cancer-treatment/hormone-therapy/hormone-therapy-the-basics. Accessed 5 May 2019
Howell A, Cuzick J, Baum M, Buzdar A, Dowset M (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62
Vasaitis TS, Bruno RD, Njar VCO (2011) CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 125(1–2):23–31
American Cancer Society (2016) Hormone therapy for prostate cancer. https://www.cancer.org/cancer/prostate-cancer/treating/hormone-therapy.html. Accessed 5 May 2019
Keskin O, Yalcin S (2013) A review of the use of somatostatin analogs in oncology. Onco Targets Ther 6:471
Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D (1982) Opiate antagonistic properties of an octapeptide somatostatin analog. Proc Natl Acad Sci 79(15):4815–4817
Lange CA, Yee D (2008) Progesterone and breast cancer. Womens Health 4(2):151–162
Lundgren S (1992) Progestins in breast cancer treatment: a Review. Acta Oncol 31(7):709–722
Brechon S (2012) The Maurer Foundation. Estrogen and breast cancer. https://www.maurerfoundation.org/estrogen-and-breast-cancer/. Accessed 5 May 2019
Lumachi F, Santeufemia DA, Basso SMM (2015) Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 6(3):231
OncoLink (2018) Taking Androgen Deprivation Therapy (ADT) for prostate cancer. https://www.oncolink.org/cancers/prostate/treatments/taking-androgen-deprivation-therapy-adt-for-prostate-cancer. Accessed 5 May 2019
Kent EC, Hussain MHA (2003) Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. Rev Urol 5(Suppl 3):S28
Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA et al (1993) Neoadjuvant therapy in cancer treatment. Cancer 72(S11):3515–3524
Johns Hopkins Medicine. Adjuvant hormonal therapy. https://www.hopkinsmedicine.org/breast_center/treatments_services/medical_oncology/adjuvant_hormonal_therapy.html. Accessed 5 May 2019
Shaikh AJ, Kumar S, Raza S, Mehboob M, Ishtiaq O (2013) Adjuvant hormonal therapy in postmenopausal women with breast cancer: physician’s choices. Int J Breast Cancer. https://doi.org/10.1155/2012/849592
Canadian Cancer Society. Side effects of hormonal therapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/hormonal-therapy/side-effects-of-hormonal-therapy/?region=on. Accessed 5 May 2019
Tavani A, La Vecchia C (1999) The adverse effects of hormone replacement therapy. Drugs Aging 114(5):347–357
National Health Service. Risks – Hormone replacement therapy (HRT). https://www.nhs.uk/conditions/hormone-replacement-therapy-hrt/risks/. Accessed 5 May 2019
National Cancer Institute. Stem cell transplants in cancer treatment. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant. Accessed 5 May 2019
Canadian Cancer Society. Stem cell transplant. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/stem-cell-transplant/?region=on. Accessed 5 May 2019
American Society of Clinical Oncology (2018) What is a bone marrow transplant (Stem cell transplant)? https://www.cancer.net/navigating-cancer-care/how-cancer-treated/bone-marrowstem-cell-transplantation/what-bone-marrow-transplant-stem-cell-transplant. Accessed 5 May 2019
Coller BS (2015) Blood at 70: its roots in the history of hematology and its birth. Blood 126(24):2548–2560
Gorer PA (1938) The antigenic basis of tumour transplantation. J Pathol Bacteriol 47(2):231–252
Jacobson LO, Marks EK, Robson MF et al (1949) Effect of spleen protection on mortality following X irradiation. J Lab Clin Med 34:58
Lorenz E, Uphoff D, Reid TR, Shelton E (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12(1):197–201
Barnes DWH (1954) What is the recovery factor in spleen? Nucleonics 12:68–71
Barnes DW, Corp MJ, Loutit JF, Neal FE (1956) Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 2(4993):626–627
Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965(25):1525–1531
Bortin MM, Bach FH, Good RA (1994) 25th anniversary of the first successful allogeneic bone marrow transplants. Bone Marrow Transplant 14(2):211–212
Lorna Benson (2013) Minnesota public radio news. John Kersey, U of M cancer research pioneer, dies. https://www.mprnews.org/story/2013/03/15/health/university-of-minnesota-cancer-research-pioneer-dies. Accessed 05 May 2019
Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE et al (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301(11):597–599
Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL et al (1980) Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302(19):1041–1046
Prentice HG, Janossy G, Price-Jones L, Trejdosiewicz LK, Panjwani D, Graphakos S et al (1984) Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 323(8375):472–476
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729–735
Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER (1980) Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 303(10):565–567
Petersdorf EW (2010) The world marrow donor association: twenty years of international collaboration for the support of unrelated donor and cord blood hematopoietic cell transplantation. Bone Marrow Transplant 45(5):807–810. https://doi.org/10.1038/bmt.2010.10
Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338(14):962–968
Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P et al (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89(8):3048–3054
Cancer Research UK. Granulocyte colony stimulating factor (G-CSF). https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/g-csf. Accessed 5 May 2019
Memorial Sloan Kettering Cancer Center. Autologous transplantation. https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/blood-stem-cell-transplantation/autologous. Accessed 5 May 2019
Leukemia Foudation (2015) Autologous stem cell transplants. https://www.leukaemia.org.au/disease-information/transplants/autologous-transplants/. Accessed 5 May 2019
Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356(11):1110–1120
Memorial Sloan Kettering Cancer Center. Allogeneic transplantation. https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/blood-stem-cell-transplantation/allogeneic. Accessed 5 May 2019
Leukemia Foundation (2018) What is an allogeneic stem cell transplant? https://www.leukaemia.org.au/disease-information/transplants/allogeneic-transplants/. Accessed 5 May 2019
National Marrow Donor Program. HLA basics. https://bethematch.org/transplant-basics/matching-patients-with-donors/how-donors-and-patients-are-matched/hla-basics/. Accessed 5 May 2019
Stavropoulos-Giokas C, Dinou A, Papassavas A (2012) The role of HLA in cord blood transplantation. Bone Marrow Res 2012:9
Bennett B (2015) Symbiotic relationships: saviour siblings, family rights and biomedicine. Aust J Fam Law 19(3):195–212
Spriggs M, Savulescu J (2002) Saviour siblings. J Med Ethics 28:289
Simaria AS, Farid S, Hassan S (2013) American pharmaceutical review. Cost-effectiveness of single-use technologies for commercial cell therapy manufacture. https://www.americanpharmaceuticalreview.com/Featured-Articles/134042-Cost-effectiveness-of-Single-Use-Technologies-for-Commercial-Cell-Therapy-Manufacture/. Accessed 5 May 2019
Park YB, Ha CW, Lee CH, Yoon YC, Park YG (2017) Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cell Transl Med 6(2):613–621
Agrawal P (2015) Stem cell therapy in drug discovery and development. J Pharmacovigilance 3:e140
Johns Hopkins Medicine (2019) Types of bone marrow transplants. https://www.hopkinsmedicine.org/kimmel_cancer_center/centers/bone_marrow_transplant/types_transplants.html. Accessed 5 May 2019
Kolb HJ (2018) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383
Ballen KK, Gluckman E, Broxmeyer HE (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122(4):491–498
Cord blood and transplants. https://bethematch.org/transplant-basics/cord-blood-and-transplants/. Accessed 5 May 2019
Kurtzberg J (2009) Update on umbilical cord blood transplantation. Curr Opin Pediatr 21(1):22–29
Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A et al (2007) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369(9577):1947–1954
Ballen K, Ahn KW, Chen M, Abdel-Azim H, Ahmed I, Aljurf M et al (2016) Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 22(9):1636–1645
Leukaemia Foundation. Haploidentical stem cell transplant. https://www.leukaemia.org.au/disease-information/transplants/haploidentical-transplant/. Accessed 5 May 2019
National Marrow Donor Program. Haploidentical transplant. https://bethematch.org/patients-and-families/about-transplant/what-is-a-bone-marrow-transplant/haploidentical-transplant/. Accessed 5 May 2019
Canadian Cancer Society. After the stem cell transplant. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/stem-cell-transplant/after-stem-cell-transplant/?region=on. Accessed 5 May 2019
Canadian Cancer Society. Side effects of a stem cell transplant. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/stem-cell-transplant/side-effects-of-stem-cell-transplant/?region=on. Accessed 5 May 2019
Canadian Cancer Society. Chemotherapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/chemotherapy/?region=on. Accessed 5 May 2019
Memorial Sloan Kettering Cancer Center. Chemotherapy. https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/chemotherapy. Accessed 5 May 2019
Cunha FI (1949) The Ebers papyrus. Am J Surg 77(1):134–136
Atta HM (1999) Edwin Smith Surgical Papyrus: the oldest known surgical treatise. Am Surg 65(12):1190–1192
Papac RJ (2001) Origins of cancer therapy. Yale J Biol Med 74(6):391–398
Riddle JM (1985) Ancient and medieval chemotherapy for cancer. Isis 76(283):319–330
McGrew RE, McGrew MP (1985) Encyclopedia of medical history. McGraw-Hill, New York
DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653
Morrison WB (2010) Cancer chemotherapy: an annotated history. J Vet Intern Med 24(6):1249–1262
Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6(Supplement 2):1–2
DeVita VT, JaEC (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653. https://doi.org/10.1158/0008-5472.CAN-07-6611
Siegel JH, McDermott WV, Steele GD, Wilmore DW, Hirsch EF, Jenkins RL et al (1990) In memoriam: George HA Clowes, Jr, MD, 1915-1988. Arch Surg 125(4):491–492
Zubrod CG, Schepartz S, Leiter J, Endicott KM, Carrese LM, Baker CG (1996) The chemotherapy program of the National Cancer Institute: history, analysis and plans. Cancer Chemother Rep 50(7):349–540
Zubrod CG, Schepartz SA, Carter SK (1977) Historical background of the National Cancer Institute’s drug development thrust. Natl Cancer Inst Monogr 45:7–11
Gilman A (1946) Therapeutic applications of chemical warfare agents. Fed Proc 5:285–292
Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT (1946) Nitrogen mustard therapy: use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Dir Assoc 132(3):126–132
Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238(23):787–793
Li MC, Hertz R, Bergenstal DM (1958) Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med 259(2):66–74
Norton L, Simon R, Brereton HD, Bogden AE (1976) Predicting the course of Gompertzian growth. Nature 264(5586):542
DeVita VT Jr (1984) On special initiatives, critics, and the National Cancer Program. Cancer Treat Rep 68(1):1
Cancer Research UK (2017) What is chemotherapy? https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/chemotherapy/what-chemotherapy-is. Accessed 5 May 2019
Teshome M, Hunt KK (2014) Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin 23(3):505–523
Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593–1598. https://doi.org/10.1056/NEJM199206113262403
Goldie JH (1987) Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14(1):1–7
Swift L, Golsteyn R (2014) Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells. Int J Mol Sci 15(3):3403–3431
Woolley PV (1998) Mechanisms of resistance to alkylating agents. Cytotechnology 27(1–3):165
Malhotra V, Perry MC (2003) Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther 2(4 Suppl 1):S2–S4
Corrie PG (2008) Cytotoxic chemotherapy: clinical aspects. Medicine 36(1):24–28
Takimoto CH, Calvo E (2008) In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds) Principles of oncologic pharmacotherapy: in cancer management, a multidisciplinary approach. PRR, Melville, New York
Shiraishi A, Sakumi K, Sekiguchi M (2000) Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 21(10):1879–1883
Yue Q-X, Liu X, Guo D-A (2010) Microtubule-binding natural products for cancer therapy. Planta Med 76(11):1037–1043
Rowinsky EK, Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52(1):35–84
Moudi M, Go R, Yien CYS et al (2013) Vinca alkaloids. Int J Prev Med 4(11):1231–1235
Qian Liu Y, Yang L, Tian X (2007) Podophyllotoxin: current perspectives. Curr Bioact Compd 3(1):37–66
Nicolaou KC, Yang Z, Liu JJ, Ueno H, Nantermet PG, Guy RK et al (1994) Total synthesis of taxol. Nature 367(6464):630
Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9(10):790–803
Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) The role of topoisomerases in DNA replication. In: Molecular Cell Biology, 4th edn. WH Freeman, New York
Pommier Y (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 109(7):2894–2902
Goodsell DS (2002) The molecular perspective: DNA topoisomerases. Stem Cells 20(5):470–471. https://doi.org/10.1634/stemcells.20-5-470
Drugs (2017) Irinotecan hydrochloride. https://www.drugs.com/monograph/irinotecan-hydrochloride.html. Accessed 5 May 2019
Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9(5):338
Drugs (2018) Etoposide. https://www.drugs.com/monograph/etoposide.html. Accessed 5 May 2019
Collins A (1990) Topoisomerase II can relax; novobiocin is a mitochondrial poison after all. BioEssays 12(10):493–494
Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63(14):4074–4081
Felix CA (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta Gene Struc Expr 1400(1–3):233–255
Doggrell SA, Davis E, Hart J, Johnston G, Hinton T, Mullaney I (2014) Cytotoxic antibiotics. https://sites.google.com/site/pharmacologyinonesemester/24-an-introduction-to-anticancer-drugs/24-3-drugs-used-in-cancer/24-3. Accessed 5 May 2019
Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54:1–7
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229
Sobell HM (1985) Actinomycin and DNA transcription. Proc Natl Acad Sci 82(16):5328–5331
Dorr RT (1992) Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 19:3–8
Verweij J, Pinedo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anti-Cancer Drugs 1(1):5–13
Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M et al (2018) Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol 126:186–200
Parker WB (2009) Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 109(7):2880–2893
Peters GJ, Van der Wilt CL, Van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87(2–3):227–253
Lind MJ (2008) Principles of cytotoxic chemotherapy. Medicine 36(1):19–23
Higdon J, Drake VJ, Delage B, McNulty H (2014) Oregon State University. Folate. https://lpi.oregonstate.edu/mic/vitamins/folate. Accessed 05 May 2019
Wagstaff AJ, Ibbotson T, Goa KL (2003) Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63(2):217–236
Koç A, Wheeler LJ, Mathews CK, Merrill GF (2004) Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J Biol Chem 279(1):223–230
Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19:1–10
Encyclopaedia Britannica (2017) Antimetabolite. https://www.britannica.com/science/antimetabolite. Accessed 05 May 2019
Barakat K, Gajewski M, Tuszynski JA (2012) DNA repair inhibitors: the next major step to improve cancer therapy. Curr Top Med Chem 12(12):1376–1390
Sánchez-Pérez I (2006) DNA repair inhibitors in cancer treatment. Clin Transl Oncol 8(9):642–646
Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6(8):1079–1099
Yildiz DA, Ozkan T, Yukselten Y, Sesli NT, Ozkanca S, Gunduz M et al (2016) Lomeguatrib, a O6-Methylguanine-DNA-methyltransferase (MGMT) inhibitor, induces DNA damage induced apoptosis by targeting double-strand DNA repair in multiple myeloma. Blood 128(22):2103
Reinhard J, Eichhorn U, Wiessler M, Kaina B (2001) Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors. Int J Cancer 93(3):373–379
Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V et al (2010) Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev 11(1):181–185
Canitrot Y, Cazaux C, Frechet M, Bouayadi K, Lesca C, Salles B et al (1998) Overexpression of DNA polymerase β in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A 95(21):12586–12590. https://doi.org/10.1073/pnas.95.21.12586
Husain I, Morton BS, Beard WA, Singhal RK, Prasad R, Wilson SH et al (1995) Specific inhibition of DNA polymerase β by its 14 kDa domain: role of single-and double-stranded DNA binding and 5′-phosphate recognition. Nucleic Acids Res 23(9):1597–1603
Barakat KH, Gajewski MM, Tuszynski JA (2012) DNA polymerase beta (pol β) inhibitors: a comprehensive overview. Drug Discov Today 17(15–16):913–920. https://doi.org/10.1016/j.drudis.2012.04.008
Iyer RR, Pluciennik A, Burdett V, Modrich PL (2006) DNA mismatch repair: functions and mechanisms. Chem Rev 106(2):302–323
Fishel R, Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5(3):382–395
Martin SA, Lord CJ, Ashworth A (2010) Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 16(21):5107–5113. https://doi.org/10.1158/1078-0432.CCR-10-0821
Takahashi M, Koi M, Balaguer F, Boland CR, Goel A (2011) MSH3 mediates sensitization of colorectal cancer cells to cisplatin, Oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 286(14):12157–12165. https://doi.org/10.1074/jbc.M110.198804
Pardo BG-GB, Aguilera A (2009) DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci 66(6):1039–1056. https://doi.org/10.1007/s00018-009-8740-3
Lieber MR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79:181–211. https://doi.org/10.1146/annurev.biochem.052308.093131
Bolderson E, Richard DJ, Zhou B-BS, Khanna KK (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15(20):6314–6320. https://doi.org/10.1158/1078-0432.CCR-09-0096
Nijman SMB (2011) Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 585(1):1–6. https://doi.org/10.1016/j.febslet.2010.11.024
Chernikova SB, Game JC, Brown JM (2012) Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther 13(2):61–68. https://doi.org/10.4161/cbt.13.2.18872
Oliveira NG, Castro M, Rodrigues AS, Gil OM, Toscano-Rico JM, Rueff J (2002) DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells. Teratog Carcinog Mutagen 22(5):343–351
Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA et al (2004) A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103(12):4659–4665
Chen X, Zhong S, Zhu X, Dziegielewska B, Ellenberger T, Wilson GM et al (2008) Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 68(9):3169–3177. https://doi.org/10.1158/0008-5472.CAN-07-6636
Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M et al (2012) An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151(7):1474–1487. https://doi.org/10.1016/j.cell.2012.11.054
Srivastava M, Raghavan SC (2015) DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol 22(1):17–29. https://doi.org/10.1016/j.chembiol.2014.11.013
Deakyne JS, Huang F, Negri J, Tolliday N, Cocklin S, Mazin AV (2013) Analysis of the activities of RAD54, a SWI2/SNF2 protein, using a specific small-molecule inhibitor. J Biol Chem 288(44):31567–31580. https://doi.org/10.1074/jbc.M113.502195
Dupré A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee J-H, Nicolette ML et al (2008) A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 4(2):119–125. https://doi.org/10.1038/nchembio.63
Zhao B, Bower MJ, McDevitt PJ, Zhao H, Davis ST, Johanson KO et al (2002) Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 277(48):46609–46615
National Cancer Institute (2015) Chemotherapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/chemotherapy. Accessed 05 May 2019
Ellis M (2014) Medical news today. Palliative chemotherapy: harms and benefits weighed in new study. https://www.medicalnewstoday.com/articles/273526.php. Accessed 05 May 2019
Canadian Cancer Society. Side effects of chemotherapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/chemotherapy/side-effects-of-chemotherapy/?region=on. Accessed 05 May 2019
National Cancer Institute (2018) Immunotherapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy#1. Accessed 05 May 2019
Canadian Cancer Society. Immunotherapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/immunotherapy/?region=on. Accessed 05 May 2019
American Society of Clinical Oncology (2019) Understanding immunotherapy. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/understanding-immunotherapy. Accessed 05 May 2019
Dance A (2017) Science. Cancer immunotherapy comes of age. https://www.sciencemag.org/features/2017/03/cancer-immunotherapy-comes-age. Accessed 05 May 2019
Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM et al (2017) Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol 8:829. https://doi.org/10.3389/fimmu.2017.00829
Targeted Oncology (2014) A brief history of immunotherapy. https://www.targetedonc.com/publications/special-reports/2014/immunotherapy-issue3/a-brief-history-of-immunotherapy. Accessed 05 May 2019
Coley WB (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 262:3–11
Shklar G, Schwartz JL, Trickler DP et al (1990) Prevention of experimental cancer and immunostimulation by vitamin E (immunosurveillance). J Oral Pathol Med 19(2):60–64
Decker WK, Safdar A (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley’s legacy revisited. Cytokine Growth Factor Rev 20(4):271–281. https://doi.org/10.1016/j.cytogfr.2009.07.004
Burnet M (1957) Cancer—a biological approach: III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1(5023):841
Friend C (1956) The isolation of a virus causing a malignant disease of the hematopoietic system in adult Swiss mice. Proc Am Assoc Cancer Res 2:106
Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18(6):769–778
Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x
Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258–267. https://doi.org/10.1098/rspb.1957.0048
Old LJ, Clarke DA, Benacerraf B (1959) Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184(4682):291–292
Graham JB, Graham RM (1959) The effect of vaccine on cancer patients. Surg Gynecol Obstet 109(2):131–138
Miller J, Mitchell GF, Weiss NS (1967) Cellular basis of the immunological defects in thymectomized mice. Nature 214(5092):992–997
Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution. J Exp Med 137(5):1142–1162
Zinkernagel RM, Doherty PC (1974) Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248:701–702
Kiessling R, Klein E, Pross H, Wigzell H (1975) “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5(2):117–121
Rodriguez V, Bodey GP, Freireich EJ et al (1978) Randomized trial of protected environment – prophylactic antibiotics in 145 adults with acute leukemia. Medicine 57(3):253–266
Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465
Grillo-Lopez A, White C, Dallaire B, Varns C, Shen C, Wei A, Leonard J et al (2000) Rituximab the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 1(1):1–9
Syn NL, Teng MWL, Mok TSK, Soo RA (2017) De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol 18(12):e731–e741. https://doi.org/10.1016/S1470-2045(17)30607-1
Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432–1433. https://doi.org/10.1126/science.342.6165.1432
Allison J, Tasuku H (2018) British society for immunology. Nobel prize 2018: cancer immunotherapy collection. https://www.immunology.org/news/nobel-prize-2018-cancer-immunotherapy-collection. Accessed 05 May 2019
Sushma M (2018) Explained: the cancer therapy that got two immunologists a Nobel. https://www.downtoearth.org.in/news/health/explained-the-cancer-therapy-that-got-two-immunologists-a-nobel-61773. Accessed 05 May 2019
Encyclopaedia Britannica (2018) Monoclonal antibodies. https://www.britannica.com/science/monoclonal-antibody. Accessed 05 May 2019
Cancer Research UK (2019) Rituximab (Mabthera, Rixathon, Truxima). https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/rituximab. Accessed 05 May 2019
Chen XCH (2016) Monoclonal antibodies for Cancer therapy approved by FDA. MOJ Immunol 4(2):00120. https://doi.org/10.15406/moji.2016.04.00120
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
Richard S, Selle F, Lotz J-P, Khalil A, Gligorov J, Soares DG (2016) Pertuzumab and trastuzumab: the rationale way to synergy. An Acad Bras Cienc 88:565–577. https://doi.org/10.1590/0001-3765201620150178
Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3):4–10
Roviello G, Sobhani N, Generali D (2017) Bevacizumab in small cell lung cancer. Ann Transl Med 5(17):361. https://doi.org/10.21037/atm.2017.06.44
Pavlidis ET, Pavlidis TE (2013) Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol 19(31):5051–5060. https://doi.org/10.3748/wjg.v19.i31.5051
Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC et al (2017) Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett 14(1):1141–1146. https://doi.org/10.3892/ol.2017.6251
Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289–304. https://doi.org/10.2165/11317600-000000000-00000
di Noia V, D’Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E (2018) Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. Expert Opin Biol Ther 18(9):937–945. https://doi.org/10.1080/14712598.2018.1508445
Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27(6):684–694
Memorial Sloan Kettering Cancer Center. Checkpoint inhibitors. https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/checkpoint-inhibitors. Accessed 05 May 2019
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Cameron F, Whiteside G, Perry C (2011) Ipilimumab: first global approval. Drugs 71(8):1093–1104
Selby K (2019) Tremelimumab. https://www.asbestos.com/treatment/immunotherapy/tremelimumab/. Accessed 05 May 2019
Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023–5039. https://doi.org/10.2147/OTT.S105862
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101(49):17174–17179
Urciuoli B (2018) FDA approves Opdivo for small cell lung cancer treatment. https://www.curetoday.com/articles/fda-approves-opdivo-for-small-cell-lung-cancer-treatment. Accessed 05 May 2019
Bristol-Myers Squibb (2018) China national drug administration approves country’s first immuno-oncology agent, Opdivo (Nivolumab injection), for previously treated non-small cell lung cancer (NSCLC). https://news.bms.com/press-release/corporatefinancial-news/china-national-drug-administration-approves-countrys-first-imm. Accessed 05 May 2019
Chemocare. Pembrolizumab. http://chemocare.com/chemotherapy/drug-info/Pembrolizumab.aspx. Accessed 05 May 2019
National Institutes of Health (2019) Study of efficacy and safety of novel spartalizumab combinations in patients with previously treated unresectable or metastatic melanoma (PLATforM). https://clinicaltrials.gov/ct2/show/NCT03484923. Accessed 05 May 2019
Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Br Med J 362:k3529. https://doi.org/10.1136/bmj.k3529
Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5(5):543–549
Goldmacher VS, Blättler WA, Lambert JM, Chari RVJ (2002) Immunotoxins and antibody-drug conjugates for cancer treatment. In: Biomedical aspects of drug targeting. Springer, Boston, pp 291–309. https://doi.org/10.1007/978-1-4757-4627-3_15
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812–1821. https://doi.org/10.1056/NEJMoa1002965
Baron J, Wang ES (2018) Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol 11(6):549–559. https://doi.org/10.1080/17512433.2018.1478725
Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res 68(22):9280–9290. https://doi.org/10.1158/0008-5472.CAN-08-1776
Larson SM, Carrasquillo JA, Cheung N-KV, Press OW (2015) Radioimmunotherapy of human tumours. Nat Rev Cancer 15(6):347–360. https://doi.org/10.1038/nrc3925
Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR et al (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31(8):742–751. https://doi.org/10.1097/CJI.0b013e31818403d5
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319(25):1676–1680
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308. https://doi.org/10.1038/nrc2355
Houot R, Schultz LM, Marabelle A, Kohrt H (2015) T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 3(10):1115–1122. https://doi.org/10.1158/2326-6066.CIR-15-0190
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917–924. https://doi.org/10.1200/JCO.2010.32.2537
Morgan RA, Chinnasamy N, Abate-Daga DD, Gros A, Robbins PF, Zheng Z et al (2013) Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133–151. https://doi.org/10.1097/CJI.0b013e3182829903
American Cancer Society (2016) Non-specific cancer immunotherapies and adjuvants. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/nonspecific-immunotherapies.html. Accessed 06 May 2019
Altundag K, Altundag O, Elkiran ET, Cengiz M, Ozisik Y (2004) Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. Med Hypotheses 63(1):56–58
Cetean S, Căinap C, Constantin A-M, Căinap S, Gherman A, Oprean L et al (2015) The importance of the granulocyte-colony stimulating factor in oncology. Clujul Med 88(4):468–472. https://doi.org/10.15386/cjmed-531
American Cancer Society (2016) Cancer vaccines. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/cancer-vaccines.html. Accessed 06 May 2019
Takes RP, Wierzbicka M, D’Souza G, Jackowska J, Silver CE, Rodrigo JP et al (2015) HPV vaccination to prevent oropharyngeal carcinoma: what can be learned from anogenital vaccination programs? Oral Oncol 51(12):1057–1060. https://doi.org/10.1016/j.oraloncology.2015.10.011
Verma R, Khanna P (2013) Human papilloma virus vaccines: need to be introduced in India. Hum Vaccin Immunother 9(1):97–99. https://doi.org/10.4161/hv.22063
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529–538
Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM et al (2009) Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 27(18S):2–2
Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17(11):3520–3526. https://doi.org/10.1158/1078-0432.CCR-10-3126
Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C et al (2014) Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66(4):677–688. https://doi.org/10.1016/j.eururo.2014.02.061
Fukuhara H, Ino Y, Todo T (2016) Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 107(10):1373–1379. https://doi.org/10.1111/cas.13027
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245–252
Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39(1):38–48. https://doi.org/10.1016/j.immuni.2013.07.004
Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ et al (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24(1):22–32. https://doi.org/10.1038/leu.2009.236
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173(3):699–703
D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082–4085
Haslett PAJ, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187(11):1885–1892
Hardy H, Harris J, Lyon E, Beal J, Foey A (2013) Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 5(6):1869–1912. https://doi.org/10.3390/nu5061869
Aleem E (2013) β-Glucans and their applications in cancer therapy: focus on human studies. Anti Cancer Agents Med Chem 13(5):709–719
Ma H-D, Deng Y-R, Tian Z, Lian Z-X (2013) Traditional Chinese medicine and immune regulation. Clin Rev Allergy Immunol 44(3):229–241. https://doi.org/10.1007/s12016-012-8332-0
Cancer Council Victoria. Immunotherapy. https://www.cancervic.org.au/cancer-information/treatments/treatments-types/immunotherapy. Accessed 06 May 2019
Cancer Research Institute. Immunotherapy by cancer type. https://www.cancerresearch.org/immunotherapy/cancer-types. Accessed 06 May 2019
Porter L, American Society of Clinical Oncology (2018) What you need to know about immunotherapy side effects. https://www.cancer.net/blog/2018-02/what-you-need-know-about-immunotherapy-side-effects. Accessed 06 May 2019
Cancer Council Victoria. Targeted therapy. https://www.cancervic.org.au/cancer-information/treatments/treatments-types/targeted-therapy. Accessed 06 May 2019
American Society of Clinical Oncology (2019) Understanding targeted therapy. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy. Accessed 06 May 2019
National Cancer Institute (2018) Targeted therapy to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#2. Accessed 06 May 2019
Canadian Cancer Society. Targeted therapy. http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/targeted-therapy/?region=on. Accessed 06 May 2019
Joo WD, Visintin I, Mor G (2013) Targeted cancer therapy–are the days of systemic chemotherapy numbered? Maturitas 76(4):308–314
Lee SL (2012) Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes 19(5):420–428. https://doi.org/10.1097/MED.0b013e328357fa0c
Jordan VC (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110(2):507–517. https://doi.org/10.1111/j.1476-5381.1993.tb13840.x
Fausel C (2007) Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm 64(24):S9–S15
Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30(1):1–4
Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171
Bae KH, Chung HJ, Park TG (2011) Nanomaterials for cancer therapy and imaging. Mol Cells 31(4):295–302
Prabhu RH, Patravale VB, Joshi MD (2015) Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 10:1001–1018. https://doi.org/10.2147/IJN.S56932
Zhou L, Huang Y, Li J, Wang Z (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27(2):255–261. https://doi.org/10.1007/s12032-009-9201-4
Zaytseva YY, Valentino JD, Gulhati P, Evers BM (2012) mTOR inhibitors in cancer therapy. Cancer Lett 319(1):1–7. https://doi.org/10.1016/j.canlet.2012.01.005
McDougall SR, Anderson ARA, Chaplain MAJ (2006) Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 241(3):564–589
Cabebe E, Wakelee H (2006) Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 42(6):387–398
Adams J, Kauffman M (2004) Development of the proteasome inhibitor Velcade™ (Bortezomib). Cancer Investig 22(2):304–311
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60–65
Baudino TA (2015) Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol 12(1):3–20
Wang J, Taylor A, Showeil R, Trivedi P, Horimoto Y, Bagwan I et al (2014) Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine 68(2):94–100. https://doi.org/10.1016/j.cyto.2014.04.005
Keating GM (2014) Bevacizumab: a review of its use in advanced cancer. Drugs 74(16):1891–1925. https://doi.org/10.1007/s40265-014-0302-9
Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6
Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117(8):2051–2058
Mitri Z, Constantine T, O’Regan R (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193. https://doi.org/10.1155/2012/743193
Dubois EA, Cohen AF (2009) Panitumumab. Br J Clin Pharmacol 68(4):482–483. https://doi.org/10.1111/j.1365-2125.2009.03492.x
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355. https://doi.org/10.1126/science.aar4060
Scheuermann RH, Racila E (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 18(5–6):385–397
Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):334–342. https://doi.org/10.1016/j.pharmthera.2012.07.013
U.S. Food and Drug Administration (2017) FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-blinatumomab-and-expands-indication-include-philadelphia-chromosome. Accessed 05 May 2019
Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A et al (2019) The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother 109:2415–2426. https://doi.org/10.1016/j.biopha
Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95(1):135–143. https://doi.org/10.3324/haematol.2008.001628
Van Der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J 7(9):e603. https://doi.org/10.1038/bcj.2017.85
Faramarz Naeim PNR, Song SX, Grody WW (2013) Principles of immunophenotyping. In: Atlas of Hematopathology, 2nd edn. Academic, London, pp 25–46
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W et al (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13(1):47–58
Jen EY, Ko C-W, Lee JE, Del Valle PL, Aydanian A, Jewell C et al (2018) FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res 24(14):3242–3246. https://doi.org/10.1158/1078-0432
Hamblin TJ (2003) CD38: what is it there for? Blood 102(6):1939–1940
Burgler S (2015) Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target. Crit Rev Immunol 35(5):417–432
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M et al (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348
Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92(4):566–567
Malaer JD, Mathew PA (2017) CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res 7(8):1637–1641
Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA (2017) Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Manag Res 9:307–314. https://doi.org/10.2147/CMAR.S117477
Wierzbicki A, Gil M, Ciesielski M, Fenstermaker RA, Kaneko Y, Rokita H et al (2008) Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J Immunol 181(9):6644–6653
Keyel ME, Reynolds CP (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics 13:1–12. https://doi.org/10.2147/BTT.S114530
Nie S, Xing Y, Kim GJ, Simons JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9:257–288
Salvador-Morales C, Gao W, Ghatalia P, Murshed F, Aizu W, Langer R et al (2009) Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther 9(2):211–221. https://doi.org/10.1586/14737140.9.2.211
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760. https://doi.org/10.1038/nnano.2007.387
Hubbell JA (2003) Enhancing drug function. Science 300(5619):595–596. https://doi.org/10.1126/science.1083625
Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18(2):456–468. https://doi.org/10.1021/bc0603539
Bisht G, Rayamajhi S (2016) ZnO nanoparticles: a promising anticancer agent. Nano 3:9. https://doi.org/10.5772/63437
Lee Y, Lee H, Kim YB, Kim J, Hyeon T, Park H, Messersmith PB, Park TG (2008) Bioinspired surface immobilization of hyaluronic acid on monodisperse magnetite nanocrystals for targeted cancer imaging. Adv Mater 20(21):4154–4157. https://doi.org/10.1002/adma.200800756
Bae KH, Lee K, Kim C, Park TG (2011) Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 32(1):176–184. https://doi.org/10.1016/j.biomaterials
Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805(1):105–117. https://doi.org/10.1016/j.bbcan.2009.11.002
Samuel N, Hudson TJ (2013) Translating genomics to the clinic: implications of cancer heterogeneity. Clin Chem 59(1):127–137. https://doi.org/10.1373/clinchem
Gray JW, Collins C, Henderson IC, Isola J, Kallioniemi A, Kallioniemi OP et al (1994) Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol 59:645–652
Örndal C, Rydholm A, Willén H, Mitelman F, Mandahl N (1994) Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet 78(2):127–137
Gorunova L, Höglund M, Andrén-Sandberg Å, Dawiskiba S, Jin Y, Mitelman F et al (1998) Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23(2):81–99
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1):R10. https://doi.org/10.1186/bcr1855
Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG et al (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15(13):4299–4311. https://doi.org/10.1158/1078-0432
Lou H, Dean M (2007) Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26(9):1357–1360
Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA, Kuo JS (2010) The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets 14(6):621–632. https://doi.org/10.1517/14712598.2010.485186
Kong D, Li Y, Wang Z, Sarkar F (2013) Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel) 3(1):716–729. https://doi.org/10.3390/cancers30100716
Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B et al (2013) Phenotypic modifications in ovarian cancer stem cells following paclitaxel treatment. Cancer Med 2(6):751–762. https://doi.org/10.1002/cam4.115
National Institutes of Health, ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. https://www.clinicaltrials.gov/. Accessed 05 May 2019
Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J (2017) Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review. PLoS Biol 15(2):e2000487. https://doi.org/10.1371/journal.pbio.2000487
American Cancer Society (2016) Side effects of targeted cancer therapy drugs. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/side-effects.html. Accessed 05 May 2019
Rogers S, Pfuderer P (1968) Use of viruses as carriers of added genetic information. Nature 219:749–751. https://doi.org/10.1038/219749a0
Friedmann T, Roblin R (1972) Gene therapy for human genetic disease? Science 175:949–955. https://doi.org/10.1126/science.175.4025.949
Rogers S (1973) Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient. J Exp Med 137:1091–1096. https://doi.org/10.1084/jem.137.4.1091
Terheggen HG, Lowenthal A, Lavinha F et al (1975) Unsuccessful trial of gene replacement in arginase deficiency. Z Kinderheilkd 119:1–3
Cepko CL, Roberts BE, Mulligan RC (1984) Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 37:1053–1062. https://doi.org/10.1016/0092-8674(84)90440-9
Wirth T, Ylä-Herttuala S (2014) Gene therapy used in Cancer treatment. Biomedicine 2:149–162. https://doi.org/10.3390/biomedicines2020149
Blaese RM, Culver KW, Miller AD et al (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270:475–480. https://doi.org/10.1126/science.270.5235.475
Sheridan C (2011) Gene therapy finds its niche. Nat Biotechnol 29:121–128. https://doi.org/10.1038/nbt.1769
Amer MH (2014) Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2:27. https://doi.org/10.1186/2052-8426-2-27
Philippidis. A 25 up-and-coming gene therapies of 2019. https://www.genengnews.com/a-lists/25-up-and-coming-gene-therapies-of-2019/. Accessed 12 Sept 2019
Ginn SL, Amaya AK, Alexander IE et al (2018) Gene therapy clinical trials worldwide to 2017: an update. J Gene Med 20:e3015. https://doi.org/10.1002/jgm.3015
Lodish H, Berk A, Zipursky SL et al (2000) Viruses: structure, function, and uses. W. H. Freeman, New York
Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346–358. https://doi.org/10.1038/nrg1066
Zabner J, Fasbender AJ, Moninger T et al (1995) Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270:18997–19007. https://doi.org/10.1074/jbc.270.32.18997
Yang W, Sun T, Cao J, Liu F (2010) Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells in vitro and in vivo. Int J Radiat Biol 86:445–457. https://doi.org/10.3109/09553001003668006
Baban CK, Cronin M, O’Hanlon D et al (2010) Bacteria as vectors for gene therapy of cancer. Bioengineered Bugs 1:385–394. https://doi.org/10.4161/bbug.1.6.13146
Pathak A, Patnaik S, Gupta KC (2009) Recent trends in non-viral vector-mediated gene delivery. Biotechnol J 4:1559–1572. https://doi.org/10.1002/biot.200900161
Das SK, Menezes ME, Bhatia S et al (2015) Gene therapies for Cancer: strategies, challenges and successes. J Cell Physiol 230:259–271. https://doi.org/10.1002/jcp.24791
Boon T (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729. https://doi.org/10.1084/jem.183.3.725
Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129. https://doi.org/10.1126/science.1129003
Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. JCO 29:917–924. https://doi.org/10.1200/JCO.2010.32.2537
Sharpe M, Mount N (2015) Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech 8:337–350. https://doi.org/10.1242/dmm.018036
Kochenderfer JN, Rosenberg SA (2013) Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10:267–276. https://doi.org/10.1038/nrclinonc.2013.46
Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709–2720. https://doi.org/10.1182/blood-2011-10-384388
Boudreau JE, Bonehill A, Thielemans K, Wan Y (2011) Engineering dendritic cells to enhance Cancer immunotherapy. Mol Ther 19:841–853. https://doi.org/10.1038/mt.2011.57
Butterfield LH, Comin-Anduix B, Vujanovic L et al (2008) Adenovirus MART-1–engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31:294–309. https://doi.org/10.1097/CJI.0b013e31816a8910
Marshall JL, Gulley JL, Arlen PM et al (2005) Phase I study of sequential vaccinations with Fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage Colony-stimulating factor, in patients with carcinoembryonic antigen–expressing carcinomas. JCO 23:720–731. https://doi.org/10.1200/JCO.2005.10.206
Norell H, Poschke I, Charo J et al (2010) Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 8:53. https://doi.org/10.1186/1479-5876-8-53
Sun E, Han R, Lu B (2018) Gene therapy of renal cancer using recombinant adeno-associated virus encoding human endostatin. Oncol Lett. https://doi.org/10.3892/ol.2018.9036
YESCARTA (axicabtagene ciloleucel) | FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel. Accessed 21 Sept 2019
KYMRIAH (tisagenlecleucel) | FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed 21 Sept 2019
Rehman H, Silk AW, Kane MP, Kaufman HL (2016) Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 4:53. https://doi.org/10.1186/s40425-016-0158-5
IMLYGIC (talimogene laherparepvec) | FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec. Accessed 21 Sept 2019
Malekshah OM, Chen X, Nomani A et al (2016) Enzyme/prodrug Systems for Cancer Gene Therapy. Curr Pharmacol Rep 2:299–308. https://doi.org/10.1007/s40495-016-0073-y
Freeman SM, Abboud CN, Whartenby KA et al (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274
Zarogoulidis P, Darwiche K (2013) Suicide gene therapy for Cancer – current strategies. J Genet Syndr Gene Ther 04:pii: 16849. https://doi.org/10.4172/2157-7412.1000139
Chen H, Beardsley GP, Coen DM (2014) Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc Natl Acad Sci U S A 111:17462–17467. https://doi.org/10.1073/pnas.1405981111
Kaliberov SA, Market JM, Gillespie GY et al (2007) Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Ther 14:1111–1119. https://doi.org/10.1038/sj.gt.3302965
Kaliberova LN, Della Manna DL, Krendelchtchikova V et al (2008) Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther 7:2845–2854. https://doi.org/10.1158/1535-7163.MCT-08-0347
Deng LY (2011) Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. WJG 17:2958. https://doi.org/10.3748/wjg.v17.i24.2958
Immonen A, Vapalahti M, Tyynelä K et al (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10:967–972. https://doi.org/10.1016/j.ymthe.2004.08.002
Aguilar LK, Shirley LA, Chung VM et al (2015) Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother 64:727–736. https://doi.org/10.1007/s00262-015-1679-3
Li BJ (2007) Vascular damage and anti-angiogenic effects of tumor vessel-targeted adenovirus-mediated herpes simplex virus thymidine kinase gene. WJG 13:4006. https://doi.org/10.3748/wjg.v13.i29.4006
Karjoo Z, Chen X, Hatefi A (2016) Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 99:113–128. https://doi.org/10.1016/j.addr.2015.05.009
Search Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=145801. Accessed 21 Sept 2019
Nemunaitis J, Tong AW, Nemunaitis M et al (2010) A phase I study of telomerase-specific replication competent oncolytic adenovirus (Telomelysin) for various solid tumors. Mol Ther 18:429–434. https://doi.org/10.1038/mt.2009.262
Clark DP, Pazdernik NJ (2016) Cancer. In: Biotechnology. Elsevier, New Jersey, pp 593–626
Levine AJ, Hu W, Feng Z (2008) Tumor suppressor genes. In: The molecular basis of cancer. Elsevier, New Jersey, pp 31–38
Cancer Genes | CancerQuest. https://www.cancerquest.org/cancer-biology/cancer-genes#table. Accessed 22 Sept 2019
Oncogene related genes – GeneCards Search Results. https://www.genecards.org/Search/Keyword?queryString=oncogene. Accessed 22 Sept 2019
Tumor suppressor gene related genes – GeneCards Search Results. https://www.genecards.org/Search/Keyword?queryString=tumor%20suppressor%20gene. Accessed 22 Sept 2019
Lange A, Lo H-W (2018) Inhibiting TRK proteins in clinical cancer therapy. Cancers 10:105. https://doi.org/10.3390/cancers10040105
Xu K, Rajagopal S, Klebba I et al (2010) The role of fibroblast Tiam1 in tumor cell invasion and metastasis. Oncogene 29:6533–6542. https://doi.org/10.1038/onc.2010.385
Minard ME, Kim L-S, Price JE, Gallick GE (2004) The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 84:21–32. https://doi.org/10.1023/B:BREA.0000018421.31632.e6
Pene-Dumitrescu T, Smithgall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to Imatinib in a kinase-dependent manner. J Biol Chem 285:21446–21457. https://doi.org/10.1074/jbc.M109.090043
Saito S, Miyaji-Yamaguchi M, Nagata K (2004) Aberrant intracellular localization of SET-CAN fusion protein, associated with a leukemia, disorganizes nuclear export. Int J Cancer 111:501–507. https://doi.org/10.1002/ijc.20296
Jun HJ, Johnson H, Bronson RT et al (2012) The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res 72:3764–3774. https://doi.org/10.1158/0008-5472.CAN-11-3990
Heider TR, Lyman S, Schoonhoven R, Behrns KE (2007) Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg 246:61–68. https://doi.org/10.1097/SLA.0b013e318070cafa
Rice KL, de Thé H (2014) The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. J Intern Med 276:61–70. https://doi.org/10.1111/joim.12208
Weekes D, Kashima TG, Zandueta C et al (2016) Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. Oncogene 35:2852–2861. https://doi.org/10.1038/onc.2015.344
Muhammad N, Bhattacharya S, Steele R et al (2017) Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma. Clin Cancer Res 23:3120–3128. https://doi.org/10.1158/1078-0432.CCR-16-2811
Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13:559–571. https://doi.org/10.1038/nrc3563
Roskoski R (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002
Ozaki T, Nakagawara A (2011) Role of p53 in cell death and human cancers. Cancers 3:994–1013. https://doi.org/10.3390/cancers3010994
Milella M, Falcone I, Conciatori F et al (2015) PTEN: multiple functions in human malignant tumors. Front Oncol 5. https://doi.org/10.3389/fonc.2015.00024
Mehta MS, Vazquez A, Kulkarni DA et al (2011) Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res Treat 125:861–868. https://doi.org/10.1007/s10549-010-1062-1
McCarthy AJ, Chetty R (2018) Smad4/DPC4. J Clin Pathol 71:661–664. https://doi.org/10.1136/jclinpath-2018-205095
Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. JCO 22:4991–5004. https://doi.org/10.1200/JCO.2004.05.061
Johannessen CM, Reczek EE, James MF et al (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. PNAS 102:8573–8578. https://doi.org/10.1073/pnas.0503224102
Kiuru M, Busam KJ (2017) The NF1 gene in tumor syndromes and melanoma. Lab Investig 97:146–157. https://doi.org/10.1038/labinvest.2016.142
Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347–355
Putney SD, Brown J, Cucco C et al (1999) Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev 9:451–458. https://doi.org/10.1089/oli.1.1999.9.451
Moreno PMD, Pêgo AP (2014) Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2:87. https://doi.org/10.3389/fchem.2014.00087
Irie A, Kijima H, Ohkawa T et al (1997) Anti-oncogene ribozymes for cancer gene therapy. Adv Pharmacol 40:207–257, Elsevier
Scherer L, Rossi JJ (2005) Cancer therapeutic applications of ribozymes and RNAi. In: Curiel DT, Douglas JT (eds) Cancer gene therapy. Humana Press, Totowa, pp 51–63
Fei Q, Zhang H, Fu L et al (2008) Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Biochim Biophys Sin 40:466–477. https://doi.org/10.1111/j.1745-7270.2008.00430.x
Cai DW, Mukhopadhyay T, Roth JA (1995) Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2:199–205
Lee S-W, Jeong J-S (2014) Use of tumor-targeting trans-splicing ribozyme for cancer treatment. In: Lafontaine D, Dubé A (eds) Therapeutic applications of ribozymes and riboswitches. Humana Press, Totowa, pp 83–95
Yan R, Qian X, Xin X et al (2002) Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells. Chin J Cancer 21:39–44
Mansoori B, Sandoghchian Shotorbani S, Baradaran B (2014) RNA interference and its role in cancer therapy. In: Advanced pharmaceutical bulletin, pp 2251–7308; eISSN. https://doi.org/10.5681/apb.2014.046
Agrawal N, Dasaradhi PVN, Mohmmed A et al (2003) RNA interference: biology, mechanism, and applications. MMBR 67:657–685. https://doi.org/10.1128/MMBR.67.4.657-685.2003
Cullen BR (2005) RNAi the natural way. Nat Genet 37:1163–1165. https://doi.org/10.1038/ng1105-1163
Rao DD, Vorhies JS, Senzer N, Nemunaitis J (2009) siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61:746–759. https://doi.org/10.1016/j.addr.2009.04.004
Beheshti Zavareh R, Sukhai MA, Hurren R et al (2012) Suppression of cancer progression by MGAT1 shRNA knockdown. PLoS One 7:e43721. https://doi.org/10.1371/journal.pone.0043721
Nemunaitis J, Barve M, Orr D et al (2014) Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver. Oncology 87:21–29. https://doi.org/10.1159/000360993
Oh J, Barve M, Matthews CM et al (2016) Phase II study of vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol 143:504–510. https://doi.org/10.1016/j.ygyno.2016.09.018
Ichim TE, Li M, Qian H et al (2004) RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 4:1227–1236. https://doi.org/10.1111/j.1600-6143.2004.00530.x
Chakraborty C, Sharma AR, Sharma G et al (2017) Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids 8:132–143. https://doi.org/10.1016/j.omtn.2017.06.005
Tabernero J, Shapiro GI, LoRusso PM et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in Cancer patients with liver involvement. Cancer Discov 3:406–417. https://doi.org/10.1158/2159-8290.CD-12-0429
Zuckerman JE, Gritli I, Tolcher A et al (2014) Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. PNAS 111:11449–11454. https://doi.org/10.1073/pnas.1411393111
Aleku M, Schulz P, Keil O et al (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits Cancer progression. Cancer Res 68:9788–9798. https://doi.org/10.1158/0008-5472.CAN-08-2428
Salva E, Ekentok C, Özbas Turan S, Akbuga J (2016) Non-viral siRNA and shRNA delivery systems in cancer therapy. In: Abdurakhmonov IY (ed) RNA interference. InTech, London
Morris LGT, Chan TA (2015) Therapeutic targeting of tumor suppressor genes: therapeutic targeting of tumors. Cancer 121:1357–1368. https://doi.org/10.1002/cncr.29140
Kazanets A, Shorstova T, Hilmi K et al (2016) Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta (BBA) – Rev Cancer 1865:275–288. https://doi.org/10.1016/j.bbcan.2016.04.001
Liu Y, Hu X, Han C et al (2015) Targeting tumor suppressor genes for cancer therapy. BioEssays 37:1277–1286. https://doi.org/10.1002/bies.201500093
Ries S, Korn WM (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86:5–11. https://doi.org/10.1038/sj.bjc.6600006
Zhang WW, Li L, Li D et al (2018) The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther 29:160–179. https://doi.org/10.1089/hum.2017.218
Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7:1–11. https://doi.org/10.1158/1541-7786.MCR-08-0423
Nag S, Zhang X, Srivenugopal KS et al (2014) Targeting MDM2-p53 interaction for Cancer therapy: are we there yet? Curr Med Chem 21:553–574
Burgess A, Chia KM, Haupt S et al (2016) Clinical overview of MDM2/X-targeted therapies. Front Oncol 6:–7. https://doi.org/10.3389/fonc.2016.00007
Zak K, Pecak A, Rys B et al (2013) Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat 23:425–448. https://doi.org/10.1517/13543776.2013.765405
Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53–62. https://doi.org/10.1016/j.tips.2010.11.004
Zandi R, Selivanova G, Christensen CL et al (2011) PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 17:2830–2841. https://doi.org/10.1158/1078-0432.CCR-10-3168
Zhao R, Choi BY, Lee M-H et al (2016) Implications of genetic and epigenetic alterations of CDKN2A (p16 INK4a ) in Cancer. EBioMedicine 8:30–39. https://doi.org/10.1016/j.ebiom.2016.04.017
Tanemura A, Terando AM, Sim M-S et al (2009) CpG Island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801–1807. https://doi.org/10.1158/1078-0432.CCR-08-1361
Pechalrieu D, Etievant C, Arimondo PB (2017) DNA methyltransferase inhibitors in cancer: from pharmacology to translational studies. Biochem Pharmacol 129:1–13. https://doi.org/10.1016/j.bcp.2016.12.004
Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18. https://doi.org/10.3390/ijms18071414
Hatch SB, Yapp C, Montenegro RC et al (2017) Assessing histone demethylase inhibitors in cells: lessons learned. Epigenetics Chromatin 10:9. https://doi.org/10.1186/s13072-017-0116-6
Pérez-Salvia M, Esteller M (2016) Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics 12:323–339. https://doi.org/10.1080/15592294.2016.1265710
Sibbald B (2001) Death but one unintended consequence of gene-therapy trial. CMAJ 164:1612
Wirth T, Hedman M, Mäkinen K et al (2006) Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Saf 1:253–257
National Health Service (2018) Complementary and alternative medicine. https://www.nhs.uk/conditions/complementary-and-alternative-medicine/. Accessed 05 May 2019
National Cancer Institute (2015) Complementary and alternative medicine. https://www.cancer.gov/about-cancer/treatment/cam. Accessed 05 May 2019
Ernst E, Cohen MH, Stone J (2004) Ethical problems arising in evidence based complementary and alternative medicine. J Med Ethics 30(2):156–159. https://doi.org/10.1136/jme.2003.007021
Gureje O, Nortje G, Makanjuola V, Oladeji BD, Seedat S, Jenkins R (2015) The role of global traditional and complementary systems of medicine in the treatment of mental health disorders. Lancet Psychiatry 2(2):168–177. https://doi.org/10.1016/S2215-0366(15)00013-9
National Center for Complementary and Integrative Health (2017) Introduction. https://nccih.nih.gov/about/strategic-plans/2016/introduction. Accessed 05 May 2019
National Center for Complementary and Alternative Medicine (2009) What is CAM? https://web.archive.org/web/20090505211246/http://nccam.nih.gov/health/whatiscam/overview.htm. Accessed 05 May 2019
Kim YJ (2017) The current studies of education for a traditional and complementary medicine in Malaysia. J Evid Based Complement Altern Med 22(4):531–537. https://doi.org/10.1177/2156587217726882
McQuade JL, Meng Z, Chen Z, Wei Q, Zhang Y, Bei W et al (2012) Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital: a survey of patients and physicians. Evid Based Complement Alternat Med 2012:11
Berman BM (2001) Complementary medicine and medical education: teaching complementary medicine offers a way of making teaching more holistic. Br Med J 322(7279):121–122. https://doi.org/10.1136/bmj.322.7279.121
Robinson N (2006) Integrated traditional Chinese medicine. Complement Ther Clin Pract 12(2):132–140
Chopra A, Doiphode VV (2002) Ayurvedic medicine. Core concept, therapeutic principles, and current relevance. Med Clin North Am 86(1):75–89
National Center for Complementary and Integrative Health (2018) Complementary, alternative, or integrative health: what’s in a name? https://nccih.nih.gov/health/integrative-health?nav=gsa. Accessed 05 May 2019
Quan H, Lai D, Johnson D, Verhoef M, Musto R (2008) Complementary and alternative medicine use among Chinese and white Canadians. Can Fam Physician 54(11):1563–1569
WebMD (2018) Whole medical systems: an overview. https://www.webmd.com/balance/guide/understanding-alternative-medicine#1. Accessed 05 May 2019
Baars EW, Hamre HJ (2017) Whole medical systems versus the system of conventional biomedicine: a critical, narrative review of similarities, differences, and factors that promote the integration process. Evid Based Complement Alternat Med 2017:4904930. https://doi.org/10.1155/2017/4904930
The Guardian (2012) Integrating the methods of traditional Chinese medicine in modern healthcare. https://www.theguardian.com/world/2012/jul/10/chinese-medicine-modern-science-cooperation. Accessed 05 May 2019
Aichun G (1999) Huangdi Neijing Suwen Jiao Zhu Yu Yi (Yellow Emperor’s Inner Classic: Plain Questions – Critically Compared, Annotated and Translated). Tianjin Kexue Jishu Chubanshe. Tianjin Science and Technology Press, Tianjin
Novella S (2012) What is traditional Chinese medicine? https://sciencebasedmedicine.org/what-is-traditional-chinese-medicine/. Accessed 05 May 2019
Liu J, Wang S, Zhang Y et al (2015) Traditional Chinese medicine and cancer: history, present situation, and development. Thorac Cancer 6(5):561–569. https://doi.org/10.1111/1759-7714.12270
Subhuti D Kampo medicine: the practice of Chinese Herbal Medicine in Japan. Institute for Traditional Medicine. http://www.itmonline.org/arts/kampo.htm. Accessed 05 May 2019
Matsuomoto M, Inoue K, Kajii E (1999) Integrating traditional medicine in Japan: the case of Kampo medicines. Complement Ther Med 4(7):254–255
Motoo Y, Seki T, Tsutani K (2011) Traditional Japanese medicine, Kampo: its history and current status. Chin J Integr Med 17(2):85–87. https://doi.org/10.1007/s11655-011-0653-y
Yamakawa J, Motoo Y, Moriya J, Ogawa M, Uenishi H, Akazawa S et al (2013) Role of Kampo medicine in integrative cancer therapy. Evid Based Complement Alternat Med 2013:570848. https://doi.org/10.1155/2013/570848
National Center for Complementary and Integrative Health (2019) Ayurvedic medicine: in depth. https://nccih.nih.gov/health/ayurveda/introduction.htm. Accessed 05 May 2019
Shah S (2019) Ayurveda: the conventional Indian Medicine System and its Global practice. Int J Innov Sci Technol 4(1):13–33. https://doi.org/10.22270/ijist.v4i1.36
Pandey MM, Rastogi S, Rawat AKS (2013) Indian traditional Ayurvedic system of medicine and nutritional supplementation. Evid Based Complement Alternat Med 2013:376327. https://doi.org/10.1155/2013/376327
Microsoft® Encarta® Online Encyclopedia (2009) Ayurveda. https://web.archive.org/web/20091028105549/http://encarta.msn.com/encyclopedia_761596196/Ayurveda.html. Accessed 05 May 2019
Jain R, Kosta S, Tiwari A (2010) Ayurveda and cancer. Pharm Res 2(6):393–394. https://doi.org/10.4103/0974-8490.75463
Rahman SZ (2001) Unani medicine in India: its origin and fundamental concepts. In: History of science, philosophy and culture in Indian civilization, vol 4 part 2. Centre for Studies in Civilizations, New Delhi, pp 298–325
Heyadri M, Hashempur MH, Ayati MH, Quintern D, Nimrouzi M, Mosavat SH (2015) The use of Chinese herbal drugs in Islamic medicine. J Integr Med 13(6):363–367
Lone AH, Ahmad T, Anwar M, Habib S, Sofi G, Imam H (2011) Leech therapy- a holistic approach of treatment in Unani (Greeko-Arab) medicine. Anc Sci Life 31(1):31
Qamar U, Aman U, Khalid MS, Rais UR (2015) Unani medicine for cancer care: an evidence-based review. IJAHM 5(3):1811–1825. https://doi.org/10.31142/ijahm
Sig AK, Guney M, Guclu AU, Ozmen E (2017) Medicinal leech therapy—an overall perspective. Integr Med Res 6(4):337–343. https://doi.org/10.1016/j.imr.2017.08.001
National Psoriasis Foundation, Whole Medical Systems. https://www.psoriasis.org/about-psoriasis/treatments/alternative/whole-systems. Accessed 05 May 2019
Smith K (2012) Homeopathy is unscientific and unethical. Bioethics 26(9):508–512. https://doi.org/10.1111/j.1467-8519.2011.01956.x
Homeopathy Research Institute, Homeopathy use around the world. https://www.hri-research.org/resources/essentialevidence/use-of-homeopathy-across-the-world/. Accessed 05 May 2019
Ernst E (2007) Homeopathy for cancer? Curr Oncol 14(4):128
Atwood KC (2003) Naturopathy: a critical appraisal. MedGenMed 5(4):39
Wahlberg A (2007) A quackery with a difference—new medical pluralism and the problem of ‘dangerous practitioners’ in the United Kingdom. Soc Sci Med 65(11):2307–2316
Ernst E (2001) Rise in popularity of complementary and alternative medicine: reasons and consequences for vaccination. Vaccine 20:S90–S93
Smith K. Naturopathic cancer treatment: integrative adjunctive cancer care. https://www.drsmithnd.com/naturopathic-cancer-treatment. Accessed 05 May 2019
Hermes BM (2016) Naturopathic cancer care – is it safe, and does it work? https://www.qualitycancertreatment.com/blog/naturopathictreatment. Accessed 05 May 2019
Kienle GS, Albonico HU, Baars E, Hamre HJ, Zimmermann P, Kiene H (2013) Anthroposophic medicine: an integrative medical system originating in Europe. Glob Adv Health Med 2(6):20–31. https://doi.org/10.7453/gahmj.2012.087
Ernst E (2006) Mistletoe as a treatment for cancer. Br Med J 333:1282. https://doi.org/10.1136/bmj.39055.493958.80
Olson JS (2002) Bathsheba’s breast: women, cancer, and history. Press, JHU
National Cancer Institute (2019) Questions and answers about mistletoe. https://www.cancer.gov/about-cancer/treatment/cam/patient/mistletoe-pdq#section/_2. Accessed 05 May 2019
NHS Specialist Pharmacy Service (2015) What is the evidence for subcutaneous mistletoe extract in the treatment of cancer? https://www.sps.nhs.uk/articles/what-is-the-evidence-for-subcutaneous-mistletoe-extract-in-the-treatment-of-cancer/. Accessed 05 May 2019
Wheeler C (2010) What is mind-body medicine? https://www.psychologytoday.com/us/blog/head-toe-happiness/201006/what-is-mind-body-medicine. Accessed 05 May 2019
National Center for Complementary and Alternative Medicine (2009) Mind-body medicine: an overview available. https://web.archive.org/web/20090506053001/http://nccam.nih.gov/health/whatiscam/mind-body/mindbody.htm. Accessed 05 May 2019
Ernst E, Pittler MH, Wider B, Boddy K (2007) Mind-body therapies: are the trial data getting stronger? Altern Ther Health Med 13(5):62–64
Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, Kappagoda CT (1999) Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. J Cardpulm Rehabil 19(4):226–234
Mundy EA, DuHamel KN, Montgomery GH (2003) The efficacy of behavioral interventions for cancer treatment-related side effects. Semin Clin Neuropsychiatry 8(4):253–275
Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L (2014) Mind-body practices in cancer care. Curr Oncol Rep 16(12):417. https://doi.org/10.1007/s11912-014-0417-x
Niggemann B, Grüber C (2003) Side-effects of complementary and alternative medicine. Allergy 58(8):707–716
Cassileth BR, Deng G (2004) Complementary and alternative therapies for cancer. Oncologist 9(1):80–89. https://doi.org/10.1634/theoncologist.9-1-80
Hughes D (2010) Alternative remedies ‘dangerous’ for kids says report. https://www.bbc.com/news/health-12060507. Accessed 05 May 2019
Ajazuddin, Saraf S (2012) Legal regulations of complementary and alternative medicines in different countries. Pharmacogn Rev 6(12):154. https://doi.org/10.4103/0973-7847.99950
National Center for Complementary and Integrative Health (2019) NCCIH 2016 strategic plan. https://nccih.nih.gov/about/strategic-plans/2016. Accessed 05 May 2019
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Peng, Y.Z., Yang, L.J., Lo, H.H., Law, B.Y.K., Wong, V.K.W. (2020). Tumor Therapeutic Modes. In: Huang, R., Wang, Y. (eds) New Nanomaterials and Techniques for Tumor-targeted Systems. Springer, Singapore. https://doi.org/10.1007/978-981-15-5159-8_6
Download citation
DOI: https://doi.org/10.1007/978-981-15-5159-8_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-5158-1
Online ISBN: 978-981-15-5159-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)